

CIRM Funded Clinical Trials

Allogeneic Cardiac-Derived Stem Cells for Patients Following a Myocardial Infarction

Disease Area:	Heart failure
Investigator:	Rachel Smith
Institution:	Capricor, Inc
CIRM Grant:	DR2A-05735
Award Value:	\$14,405,857
Trial Sponsor:	Capricor, Inc
Trial Stage:	Phase 2
Trial Status:	Active, not recruiting
Targeted Enrollment:	134
ClinicalTrials.gov ID:	NCT01458405



Rachel Smith

Details:

In this trial, Capricor Therapeutics used donor cells derived from the heart to treat patients at risk for developing heart failure after a heart attack. In previous clinical studies, the cells appeared to reduce scar tissue, promote blood vessel growth and improve heart function. This trial is ending after failing to achieve its primary goal of reduction of scar size in the heart.

Design:

Randomized, double-blind placebo-controlled. Intra-coronary delivery, single dose.

Goal:

Primary: Determine whether treatment is safe and causes reduction in cardiac scar size in patients with heart failure after a heart attack.
Secondary: Assess for other structural or functional cardiac benefits.

Updates:

This study is ongoing, but not recruiting participants.

[Contact Trial Sponsor](#)

Source URL: <http://www.cirm.ca.gov/clinical-trial/allogeneic-cardiac-derived-stem-cells-patients-following-myocardial-infarction>